Lymphatic filariasis is major public concern targeted for global elimination by 2020. Additional effect of triple-drug regimen (ivermectin, diethylcarbamazine, and albendazole) at the population level to achieve elimination targets with fewer rounds of mass treatment compared to standard two-drug regimen is a crucial. The study determined the potential benefit of the triple-drug regimen over the two-drug regimen in accelerating lymphatic filariasis elimination in different epidemiological settings.
Three different models (LYMFASIM, EPIFIL, and TRANSFIL) of lymphatic filariasis transmission was used to analyse the projected effects mass drug administration with triple-drug regimen over standard two-drug regimens. The primary outcome was number of mass drug round required to reduce target prevalence of microfilariae to >1% The target prevalence after three round of two drug regimen was…
